MAP2K7 and lung carcinoma: With the advent of U.S. Food and Drug Administration (FDA)-approved covalent KRASG12C inhibitors, it is imperative to investigate whether autophagy occurs following inhibition of KRASG12C signaling, especially since MEK inhibitors offer little clinical benefit accompanied by toxicity to lung cancer patients (Blumenschein et al., 2015).